<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charlotte Cunningham-Rundles, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Luigi D Notarangelo, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 29, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Common variable immunodeficiency (CVID) is an inborn error of immunity (also called primary immunodeficiency) characterized by impaired B cell differentiation with defective immunoglobulin production. It is the most prevalent form of significant antibody deficiency affecting both children and adults. "Variable" refers to the heterogeneous clinical manifestations of this disorder, which include recurrent infections, chronic lung disease, autoimmune disorders, gastrointestinal disease, and a heightened susceptibility to lymphoma.</p><p>The clinical manifestations, epidemiology, evaluation, and diagnosis of CVID will be discussed here, with a focus on presentation in adult patients. Issues that are particularly relevant to children are reviewed separately. The pathogenesis and treatment are also presented separately. (See  <a class="medical medical_review" href="/d/html/16132.html" rel="external">"Common variable immunodeficiency in children"</a> and  <a class="medical medical_review" href="/d/html/3904.html" rel="external">"Pathogenesis of common variable immunodeficiency"</a> and  <a class="medical medical_review" href="/d/html/3952.html" rel="external">"Treatment and prognosis of common variable immunodeficiency"</a>.)</p><p class="headingAnchor" id="H1191858"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>CVID (MIM# 240500) is not a single disease but rather a collection of hypogammaglobulinemia syndromes resulting from many genetic defects. In approximately 25 percent of cases, specific molecular defects have been identified, although, in the majority, the causes are unknown. CVID has been defined by the following laboratory criteria [<a href="#rid1">1,2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Markedly reduced serum concentrations of immunoglobulin G (IgG), in combination with low levels of immunoglobulin A (IgA) and/or immunoglobulin M (IgM)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Poor or absent response to immunizations</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An absence of any other defined immunodeficiency state</p><p></p><p>Etiologic and genetic factors underlying CVID are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/3904.html" rel="external">"Pathogenesis of common variable immunodeficiency"</a>.)</p><p class="headingAnchor" id="H1191865"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>CVID is estimated to affect as many as 1 in 25,000 individuals [<a href="#rid3">3-5</a>]. There is some evidence of higher prevalence among individuals of Northern European descent [<a href="#rid3">3,5,6</a>]. Internet-based registries and databases of patients with inborn errors of immunity have been established by the Immune Deficiency Foundation in the United States (USIDNET) and the European Society for Immunodeficiencies (ESID); in both, CVID is the most common diagnosis, affecting more than 20 percent of registered patients [<a href="#rid5">5,7,8</a>].</p><p>CVID is sometimes diagnosed in childhood but more typically after puberty. In an analysis of the CVID data from the ESID registry collected between the years of 2004 and 2012, 34 percent of patients were diagnosed before 10 years of age [<a href="#rid5">5</a>]. In studies from United States centers, approximately 20 percent of patients are diagnosed before the age of 20 years. The majority of patients are diagnosed between the ages of 20 and 45 years [<a href="#rid9">9,10</a>].</p><p>The clinical manifestations of CVID affect multiple organ systems, and patients often have been evaluated by several specialists by the time they are diagnosed. Perhaps partly for this reason, delayed recognition of this disease is common. In the above study, there was an average of five to seven years between onset of symptoms and diagnosis [<a href="#rid5">5,6,9</a>]. More recent data reported a median diagnostic delay of 4.1 years [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H178471451"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>In addition to recurrent infections, approximately one-half of patients with CVID also have evidence of immune dysregulation leading to autoimmunity, a variety of inflammatory disorders, and/or malignant disease. Accordingly, CVID can present with disorders in each of these categories. Patients may suffer from chronic lung disease, gastrointestinal and liver disorders, granulomatous infiltrations of several organs, lymphoid hyperplasia, splenomegaly, or malignancy [<a href="#rid3">3,4,9-13</a>].</p><p>Among 902 patients in the European Society for Immunodeficiencies (ESID) database for whom data were available, the most common reported disorders were pneumonia, autoimmunity, splenomegaly, and bronchiectasis (32, 29, 26, and 23 percent, respectively) [<a href="#rid5">5</a>].</p><p>In a series of 473 patients from one center, the following disorders were diagnosed over the course of 40 years [<a href="#rid10">10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Infections (94 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Hematologic or organ-specific autoimmunity (29 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic lung disease (29 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Bronchiectasis (11 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal inflammatory disease (15 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Malabsorption (6 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Granulomatous disease (10 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Liver disease/hepatitis (9 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Lymphoma (8 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Other cancers (7 percent)</p><p></p><p class="headingAnchor" id="H1193458"><span class="h2">Infections</span><span class="headingEndMark"> — </span>Individuals with CVID may present with recurrent infections affecting different organ systems, especially the upper and lower respiratory tracts and/or gastrointestinal tract  (<a class="graphic graphic_table graphicRef89794" href="/d/graphic/89794.html" rel="external">table 1</a>). In a series of 473 patients, 32 percent had infections as their only manifestation of CVID [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H25083002"><span class="h3">Most common pathogens</span><span class="headingEndMark"> — </span>Nearly all patients develop bacterial infections (specific organisms are discussed below). Other common infections include giardiasis and <em>Mycoplasma</em> and, more recently, norovirus.</p><p class="headingAnchor" id="H25083082"><span class="h4">Other pathogens</span><span class="headingEndMark"> — </span>Unusual or opportunistic infections with viral and fungal pathogens are uncommon. T cell dysfunction is variable in patients with CVID, and in vitro estimates of T cell function may not necessarily correlate with patients' clinical history. <em>Cryptosporidia</em>, <em>Pneumocystis</em> pneumonia, and severe herpes zoster (shingles) have been reported, even in patients who do not have laboratory abnormalities indicative of decreased T cell numbers or depressed T cell function [<a href="#rid6">6,14,15</a>].</p><p class="headingAnchor" id="H25083016"><span class="h3">Sinopulmonary infections</span><span class="headingEndMark"> — </span>Sinopulmonary infections, including pneumonia, bronchitis, and sinusitis, as well as otitis and conjunctivitis, are observed in the majority of patients with CVID [<a href="#rid5">5,6,13,15</a>]. These infections may be acute, chronic, or recurrent. Patients are particularly susceptible to infection with the encapsulated bacteria, <em>Streptococcus pneumoniae</em> and <em>Haemophilus influenzae</em>, and with atypical bacteria from the <em>Mycoplasma</em> species [<a href="#rid6">6,7,15-20</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pneumonia</strong> – Over three-quarters of patients have had at least one episode of bacterial pneumonia prior to diagnosis [<a href="#rid6">6,9,16,20,21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rhinosinusitis/otitis media</strong> – Both acute and chronic rhinosinusitis and otitis media are common, particularly in untreated CVID patients. Patients with longstanding disease may develop hearing loss.</p><p></p><p class="bulletIndent1">Often, multiple pathogens are responsible, including both bacteria and viruses, with rhinovirus being the most common [<a href="#rid22">22</a>]. It is unclear if patients with CVID suffer from more frequent or severe infections with viruses causing common colds.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Conjunctivitis</strong> – Chronic or recurrent conjunctivitis in patients with CVID is principally due to nonencapsulated <em>H. influenzae</em> [<a href="#rid9">9,12</a>].</p><p></p><p class="headingAnchor" id="H25083192"><span class="h3">Gastrointestinal infections</span><span class="headingEndMark"> — </span>Causes of acute diarrhea in patients with CVID include infections with norovirus, <em>Campylobacter jejuni</em>, or <em>Salmonella</em>. (See  <a class="medical medical_review" href="/d/html/2717.html" rel="external">"Approach to the adult with acute diarrhea in resource-abundant settings"</a>.)</p><p>Chronic giardiasis causing refractory diarrhea, malabsorption, and/or weight loss has been reported in patients with CVID [<a href="#rid5">5,23,24</a>]. Other infections causing chronic diarrhea include cytomegalovirus or, rarely, <em>Cryptosporidium</em> or norovirus [<a href="#rid9">9,23-26</a>]. However, many gastrointestinal symptoms cannot be attributed to an infectious etiology. (See <a class="local">'Gastrointestinal disease'</a> below.)</p><p class="headingAnchor" id="H25083250"><span class="h3">Other infectious disorders</span><span class="headingEndMark"> — </span>Other infectious disorders reported in patients with CVID include septic arthritis, meningitis (both bacterial and viral), and sepsis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Septic arthritis</strong> – Streptococci or <em>Mycoplasma</em> can cause septic arthritis (as well as respiratory infections) in patients with CVID [<a href="#rid4">4,17,27,28</a>]. The presentation can range from acute monoarthritis that responds rapidly to antibiotic therapy or, for <em>Mycoplasma</em>, to erosive, chronic polyarthritis that is resistant to treatment [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/d/html/7666.html" rel="external">"Septic arthritis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bacterial meningitis/sepsis</strong> – Bacterial meningitis and sepsis were reported in CVID patients, mostly before treatment with <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> therapy became available [<a href="#rid4">4,9,29,30</a>]. (See  <a class="medical medical_review" href="/d/html/1287.html" rel="external">"Clinical features and diagnosis of acute bacterial meningitis in adults"</a>.)</p><p></p><p class="headingAnchor" id="H1193479"><span class="h2">Pulmonary disease</span><span class="headingEndMark"> — </span>Chronic lung disease is a common problem in patients with CVID and can lead to recurrent hospitalizations and significant morbidity [<a href="#rid4">4,10,13,31-33</a>]. It has historically been a leading cause of death in these patients [<a href="#rid4">4,9,29</a>].</p><p>Approximately one-third have chronic lung disease by the time of diagnosis. For example, in one study of 224 patients, 34 percent had chronic lung disease at the time of diagnosis, which increased to 46 percent during a mean follow-up of 11 years [<a href="#rid17">17</a>]. In another large series of 248 patients, 27 percent had either bronchiectasis or restrictive or obstructive lung disease [<a href="#rid9">9</a>].</p><p>The respiratory manifestations of CVID follow two main mechanisms: injury due to acute or recurrent infections and damage due to poorly understood immune-mediated processes. Because of this, there are two types of chronic lung disease, bronchiectasis and interstitial lung disease (ILD), which are best distinguished by chest computed tomography (CT). In retrospective studies, they can be associated with different immune phenotypes. Bronchiectasis is more often found in older subjects (as this may reflect longer-term damage) and ILD in younger subjects, who often have a history of autoimmune cytopenias, increased serum IgM levels, and lower CD3 T cell counts [<a href="#rid34">34-37</a>]. In terms of prevalence, bronchiectasis was found in a 54 percent of a large CVID cohort in one study [<a href="#rid17">17</a>]; a subsequent study found it to be present in 61 percent [<a href="#rid38">38</a>].</p><p>Issues related to pulmonary diseases in patients with inborn errors of immunity are reviewed separately. (See  <a class="medical medical_review" href="/d/html/15830.html" rel="external">"Pulmonary complications of primary immunodeficiencies"</a>.)</p><p class="headingAnchor" id="H1739587212"><span class="h3">Obstructive diseases</span><span class="headingEndMark"> — </span>An obstructive pattern on spirometry in patients with CVID can accompany asthma, bronchiectasis, or other lung processes. Therefore, additional evaluation, such as bronchodilator challenge to demonstrate reversibility or bronchial provocation testing, may be needed to diagnose asthma conclusively [<a href="#rid37">37,39</a>]. (See  <a class="medical medical_review" href="/d/html/1444.html" rel="external">"Clinical manifestations and diagnosis of bronchiectasis in adults"</a> and  <a class="medical medical_review" href="/d/html/1435.html" rel="external">"Bronchiectasis in adults: Treatment of acute and recurrent exacerbations"</a>.)</p><p class="headingAnchor" id="H3512698873"><span class="h3">Restrictive diseases</span><span class="headingEndMark"> — </span>Restrictive changes on pulmonary function testing may indicate the presence of an inflammatory lung disease. Restrictive defects may result from lymphocytic or granulomatous infiltrates or both. Other causes of restrictive changes include mucous plugging or postsurgery restriction. On pulmonary imaging, features of ILD in patients with CVID include reticular, nodular, or ground glass opacities.</p><p class="headingAnchor" id="H2960990378"><span class="h4">Interstitial lung disease</span><span class="headingEndMark"> — </span>The prevalence of ILD is increased in patients with CVID. This may include lymphocytic infiltrates with or without granulomata. In one retrospective study, 2 of 18 patients with biopsy-proven granuloma in one or more tissue sites had ILD on high-resolution CT. Thirteen patients had diffuse reticulation, which varied from fine to coarse with features of fibrosis, while eight had nodules [<a href="#rid40">40,41</a>]. In another study, lung tissues of four of six patients with ILD contained poorly formed granulomata and variable T/B ratios, and several had B cell follicles with the characteristics of ectopic germinal centers [<a href="#rid42">42</a>]. Assessment and monitoring of lung disease requires diagnostic and management guidelines, which have been outlined [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H2498062023"><span class="h3">Granulomatous lung disease</span><span class="headingEndMark"> — </span>When both lymphocytic ILD and granuloma are present on a lung biopsy, the term "granulomatous-lymphocytic interstitial lung disease" (GLILD) has been used [<a href="#rid44">44,45</a>]. GLILD was defined as "a distinct clinico-radio-pathologic interstitial lung disease occurring in patients with CVID, associated with a lymphocytic infiltrate and/or granuloma of the lung, and in whom other conditions have been considered and were possibly excluded" in a 2017 British consensus statement [<a href="#rid46">46</a>]. GLILD is a common cause of diffuse parenchymal lung disease in patients with CVID. It typically presents in patients between the ages of 20 and 50 years with the gradual development of dyspnea on exertion with new or altered cough, although some patients are asymptomatic when characteristic findings are first detected on chest imaging. GLILD is more common in CVID subjects with history of autoimmune cytopenia, hypersplenism, polyarthritis, lower marginal zone and switched memory B cells, and restrictive lung function [<a href="#rid47">47,48</a>]. (See  <a class="medical medical_review" href="/d/html/15830.html" rel="external">"Pulmonary complications of primary immunodeficiencies", section on 'Granulomatous and lymphocytic interstitial lung disease'</a>.)</p><p class="headingAnchor" id="H1673980030"><span class="h2">Extrapulmonary granulomas</span><span class="headingEndMark"> — </span>Patients with CVID, with or without granulomatous lung disease, may also have or develop noncaseating granulomas in the lymphoid or solid organs, including the lymph nodes, spleen, liver, intestine, brain, eyes, or skin [<a href="#rid40">40,49-51</a>]. It is estimated that 8 to 20 percent of CVID patients have some form of granulomatous disease, although the prevalence is probably underappreciated since most tissues are not biopsied [<a href="#rid5">5,13,51</a>]. Common presentations besides pulmonary symptoms are lymphadenopathy and splenomegaly. In the United States, patients with granulomatous disease in CVID appear to have higher rates of autoimmune disorders as well, such as immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA) [<a href="#rid40">40,49</a>].</p><p>When granuloma are found in tissues, clinicians may have diagnosed this as "sarcoid," but the current view is that the immune defect is the underlying cause of these tissue changes; there are also significant differences between "sarcoidosis" and the granulomatous disease that may accompany CVID. These commonly include hyperglobulinemia in sarcoidosis, for example. Some patients may have variable elevations in angiotensin-converting enzyme (ACE) levels, but this is not diagnostic [<a href="#rid40">40,49,52</a>], as these are found in other immunodeficient subjects with no history of granuloma, as well as approximately 75 percent of patients with sarcoidosis. One series found 8 cases of CVID among 80 patients with sarcoidosis, with 22 other cases reported in the literature [<a href="#rid52">52</a>]. Therefore, patients with apparent sarcoidosis who are hypogammaglobulinemic and have recurrent infections should be evaluated for CVID [<a href="#rid53">53</a>].</p><p>The pathogenesis of noncaseating granulomas in CVID is not known. An unusual tumor necrosis factor (TNF) polymorphism was found in some increased numbers, but effects on serum TNF levels were not examined [<a href="#rid54">54</a>]. An abnormal CD8+ T cell response to cytomegalovirus has also been detected in patients with CVID and inflammatory disease [<a href="#rid55">55</a>].</p><p class="headingAnchor" id="H9597804"><span class="h2">Gastrointestinal disease</span><span class="headingEndMark"> — </span>Gastrointestinal disease is identified in approximately 10 to 20 percent of CVID patients and may be the presenting disorder in some [<a href="#rid9">9,12,23,24,26,56-58</a>]. Diarrhea is the most common symptom, with malabsorption and weight loss also reported. Vitamin and electrolyte deficiencies may result in severe cases. Specific disorders include (in decreasing order of prevalence):</p><p class="bulletIndent1"><span class="glyph">●</span>Inflammatory bowel-like disease, which may resemble ulcerative colitis, ulcerative proctitis, Crohn-like disease, or microscopic colitis</p><p class="bulletIndent1"><span class="glyph">●</span>Sprue-like illness with flat villi</p><p class="bulletIndent1"><span class="glyph">●</span>Nodular lymphoid hyperplasia  (<a class="graphic graphic_picture graphicRef80570" href="/d/graphic/80570.html" rel="external">picture 1</a>) [<a href="#rid59">59,60</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Pernicious anemia</p><p class="bulletIndent1"><span class="glyph">●</span>Bacterial overgrowth</p><p class="bulletIndent1"><span class="glyph">●</span>Protein-losing enteropathy</p><p class="bulletIndent1"><span class="glyph">●</span>Nonspecific malabsorption</p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal lymphoma</p><p></p><p>The gastrointestinal manifestations of inborn errors of immunity are reviewed separately. (See  <a class="medical medical_review" href="/d/html/99315.html" rel="external">"Gastrointestinal manifestations in primary immunodeficiency"</a>.)</p><p>Specific disorders are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/4743.html" rel="external">"Clinical presentation and diagnosis of primary gastrointestinal lymphomas", section on 'Predisposing conditions'</a> and  <a class="medical medical_review" href="/d/html/4070.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults"</a> and  <a class="medical medical_review" href="/d/html/4067.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults"</a> and  <a class="medical medical_review" href="/d/html/4774.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in adults"</a>.)</p><p>The pathophysiology of many of these gastrointestinal disorders is not understood, although defects in cellular immunity, rather than antibody deficiency alone, may predispose patients to such illnesses [<a href="#rid57">57,61,62</a>]. In the data from the ESID registry, enteropathy was associated with autoimmunity and with low serum IgM but not with low serum IgA [<a href="#rid5">5</a>]. Patients with very low total memory B cells and low switched memory B cells appear more likely to develop malabsorption or chronic diarrhea than patients with normal memory B cells [<a href="#rid63">63</a>]. (See <a class="local">'Additional testing'</a> below.)</p><p class="headingAnchor" id="H1193493"><span class="h2">Autoimmune disease</span><span class="headingEndMark"> — </span>Autoimmune conditions are diagnosed in 25 to 30 percent of CVID patients and can be the presenting disorder [<a href="#rid64">64-66</a>]. For unclear reasons, these patients seem to be less likely to have a history of repeated infections [<a href="#rid10">10</a>] and may be more likely to have enteropathy [<a href="#rid5">5</a>]. Autoimmunity is a manifestation of immune dysregulation, although the specific mechanisms for this heightened susceptibility in CVID are not known. The most frequently diagnosed disorders are  (<a class="graphic graphic_table graphicRef81925" href="/d/graphic/81925.html" rel="external">table 2</a>) [<a href="#rid9">9,10,65,66</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>ITP and AIHA [<a href="#rid65">65,67,68</a>] (see  <a class="medical medical_review" href="/d/html/7076.html" rel="external">"Diagnosis of hemolytic anemia in adults"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Rheumatoid arthritis and rheumatoid-like arthritis [<a href="#rid69">69</a>] (see  <a class="medical medical_review" href="/d/html/7502.html" rel="external">"Clinical manifestations of rheumatoid arthritis"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Pernicious anemia [<a href="#rid9">9,12</a>] (see  <a class="medical medical_review" href="/d/html/7154.html" rel="external">"Treatment of vitamin B12 and folate deficiencies"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Autoimmune thyroiditis [<a href="#rid65">65</a>] (see  <a class="medical medical_review" href="/d/html/7854.html" rel="external">"Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Vitiligo [<a href="#rid70">70</a>] (see  <a class="medical medical_review" href="/d/html/105109.html" rel="external">"Vitiligo: Pathogenesis, clinical features, and diagnosis"</a>)</p><p></p><p>Autoimmune hematologic disorders are the most common autoimmune conditions in these patients. A review of 326 CVID patients found that 11 percent had a history of ITP, AIHA, or Evans syndrome [<a href="#rid67">67</a>]. Approximately one-half of these developed hematologic autoimmune disease before or concurrent with the diagnosis of CVID. A small case-control study suggested that patients presenting with AIHA initially may represent a distinct phenotype, with lower rates of recurrent infections but higher rates of splenomegaly, other autoimmune conditions, and lymphoma [<a href="#rid68">68</a>]. Autoimmune disorders in children with CVID are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/16132.html" rel="external">"Common variable immunodeficiency in children", section on 'Autoimmune disease'</a>.)</p><p>CVID may also be identified in rare patients who were previously diagnosed with systemic lupus erythematosus (SLE) [<a href="#rid71">71</a>]. In most cases, the SLE appeared to precede the CVID, and it remains unclear if immunosuppressive or glucocorticoid therapy in SLE patients could cause the development of hypogammaglobulinemia and immune defects or if the two conditions are arising from a common underlying defect.</p><p>Other autoimmune conditions that have been reported in CVID patients include inflammatory bowel disease, juvenile idiopathic arthritis, Sjögren's disease, vitiligo, reactive arthritis (formerly Reiter syndrome), autoimmune hepatitis, and autoimmune neutropenia [<a href="#rid65">65</a>].</p><p>The spectrum of autoimmune disease associated with inborn errors of immunity is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/16362.html" rel="external">"Autoimmunity in patients with inborn errors of immunity/primary immunodeficiency"</a>.)</p><p class="headingAnchor" id="H1193507"><span class="h2">Allergic disease</span><span class="headingEndMark"> — </span>Patients with CVID can have signs and symptoms consistent with allergic diseases, especially allergic rhinitis and asthma, although allergic disease is less common than in people without CVID. Diagnosis may not be straightforward, because, despite a consistent clinical presentation, most patients have low or undetectable levels of serum immunoglobulin E (IgE) and negative skin test results. In fact, one study noted that the presence of IgE was an indicator that CVID was not the diagnosis [<a href="#rid72">72</a>]. Another study demonstrated that some patients with CVID and symptoms suggestive of allergic asthma had low or undetectable total IgE and negative in vitro tests for allergen-specific IgE and yet still developed symptoms to bronchoprovocation tests with allergen [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H1193514"><span class="h2">Lymphadenopathy/splenomegaly</span><span class="headingEndMark"> — </span>Splenomegaly and lymphadenopathy are common in CVID patients, although the pathogenesis of this finding is not known. One report of 224 CVID patients showed that 26 percent had an enlarged spleen by ultrasound [<a href="#rid17">17</a>]. Splenomegaly was most closely associated with granulomatous disease (of various organs) in the ESID registry analysis [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H1193521"><span class="h2">Liver disease</span><span class="headingEndMark"> — </span>Approximately 10 percent of patients have significant liver dysfunction, with elevations in alkaline phosphatase being common [<a href="#rid73">73</a>]. The most common liver pathology in CVID appears to be nodular regenerative hyperplasia, a poorly understood cause of portal hypertension [<a href="#rid74">74,75</a>]. Patients typically present with anicteric cholestasis and/or portal hypertension. In a series of CVID patients with evidence of liver dysfunction, biopsies revealed idiopathic noncirrhotic portal hypertension (including nodular regenerative hyperplasia) in many [<a href="#rid74">74,75</a>]. These patients appeared to have higher rates of autoimmune disease and nonceliac enteropathy compared with CVID patients without liver disease. Hepatitis B and C virus infection, primary biliary cholangitis, and granulomatous liver disease have also been reported [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/3580.html" rel="external">"Noncirrhotic portal hypertension", section on 'Idiopathic noncirrhotic portal hypertension/Porto-sinusoidal vascular disease'</a>.)</p><p class="headingAnchor" id="H1193528"><span class="h2">Malignancies</span><span class="headingEndMark"> — </span>An increased risk of malignancies is reported in CVID. In a large European study, the relative risk of cancer at all sites was 1.8, with an absence of an increased risk among relatives, suggesting that the effect was due to CVID [<a href="#rid76">76</a>]. Non-Hodgkin lymphomas (NHLs) are most common. In another large, European collaborative study of 334 CVID patients, having a form of polyclonal lymphocytic infiltration was associated with a fivefold increased risk of lymphoid malignancy [<a href="#rid12">12</a>]. In addition, there was a correlation between higher serum IgM levels and the eventual development of either polyclonal lymphocytic infiltration or lymphoid malignancy.</p><p class="headingAnchor" id="H1193535"><span class="h3">Non-Hodgkin lymphomas</span><span class="headingEndMark"> — </span>NHLs occur at a markedly increased rate among patients with CVID, although the precise incidence is difficult to determine [<a href="#rid77">77-79</a>]. In a large clinical study of 248 patients with CVID, 8 percent of patients developed NHL over variable periods of time [<a href="#rid10">10</a>]. Another study estimated that females had a 438-fold increased risk of developing NHL compared with the age-adjusted expected incidence [<a href="#rid80">80</a>]. An update of this single-center study of 647 CVID subjects reported 45 patients (15 males and 30 females; 7 percent) with 49 lymphoid malignancies. The mean age at CVID diagnosis was 42.6 years and at lymphoma diagnosis 48.8 years [<a href="#rid81">81</a>]. Clusters of NHL within families affected by CVID have also been reported [<a href="#rid82">82</a>]. In clinical practice, it is important to tell patients that the risk of lymphoma is elevated (possibly 2 to 8 percent lifetime risk [<a href="#rid9">9</a>]) and review with them common signs and symptoms, such as fever, weight loss, night sweats, and persistent swellings of the lymph nodes or abdomen (due to hepatomegaly or splenomegaly).</p><p>The NHLs that occur in patients with CVID are mostly extranodal in origin, well differentiated, and of B cell origin [<a href="#rid9">9,81,82</a>]. (See  <a class="medical medical_review" href="/d/html/4695.html" rel="external">"Clinical presentation and initial evaluation of non-Hodgkin lymphoma"</a>.)</p><p>An association exists between NHL and other congenital immunodeficiency diseases, although principally those with prominent T cell defects. These include ataxia-telangiectasia, Wiskott-Aldrich syndrome, X-linked lymphoproliferative disease, and severe combined immunodeficiency [<a href="#rid76">76</a>]. (See  <a class="medical medical_review" href="/d/html/6233.html" rel="external">"Ataxia-telangiectasia"</a> and  <a class="medical medical_review" href="/d/html/3953.html" rel="external">"Wiskott-Aldrich syndrome"</a> and  <a class="medical medical_review" href="/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview"</a>.)</p><p class="headingAnchor" id="H1193542"><span class="h3">Gastric cancers</span><span class="headingEndMark"> — </span>An increased risk of gastric cancer has been reported in some studies of CVID patients [<a href="#rid4">4,17,83-85</a>]. This may have been related to the increased frequency of pernicious anemia or <em>Helicobacter pylori</em> infection as a study of 34 CVID patients with dyspepsia found that 41 percent had biopsy-proven <em>H. pylori</em> [<a href="#rid85">85</a>]. In these patients, the infection was significantly associated with multifocal atrophic gastritis, which is associated with gastric carcinoma. Common presenting symptoms of gastric cancer include abdominal pain, weight loss, and dyspepsia. However, the incidence of this cancer may be decreasing, as suggested by a 2010 study of 476 patients with CVID in which gastric cancer was diagnosed in only 0.6 percent of patients, whereas NHL developed in 6.7 percent [<a href="#rid86">86</a>]. (See  <a class="medical medical_review" href="/d/html/2513.html" rel="external">"Clinical features, diagnosis, and staging of gastric cancer"</a>.)</p><p class="headingAnchor" id="H25760170"><span class="h1">PHYSICAL EXAMINATION</span><span class="headingEndMark"> — </span>Physical examination of patients with CVID may be normal, or there may be signs and symptoms of chronic illness (eg, failure to thrive or growth retardation in children, weight loss in adults) [<a href="#rid30">30,87</a>]. Other common abnormalities include nasal discharge or congestion signifying chronic sinusitis, scarring of the tympanic membranes, and/or digital clubbing signifying chronic pulmonary disease. Additional findings that may be noted in some patients include lymphadenopathy, splenomegaly, arthritis, conjunctivitis, and skin findings associated with autoimmune disease. Oral thrush is uncommon.</p><p class="headingAnchor" id="H1196168"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>The initial laboratory evaluation of patients with CVID involves the measurement of immunoglobulin levels, the demonstration of impaired responses to vaccinations, and exclusion of other causes of these abnormalities.</p><p class="headingAnchor" id="H1196176"><span class="h2">Routine laboratories</span><span class="headingEndMark"> — </span>Patients with CVID may not generally have abnormalities in routine laboratories, such as complete blood counts, serum chemistries, electrolytes, or urinalysis, in the absence of a specific associated condition. Reductions in albumin or total protein level may be seen, and lymphopenia may develop over time, but these are not reliable abnormalities. Elevations in C-reactive protein are seen with infection. Liver transaminases and alkaline phosphatase may be variably elevated and should be monitored if increased, as elevations may signal the development of nodular regenerative hyperplasia. (See <a class="local">'Liver disease'</a> above.)</p><p class="headingAnchor" id="H3"><span class="h2">Immunoglobulin levels</span><span class="headingEndMark"> — </span>By definition, serum immunoglobulin levels are markedly abnormal in patients with CVID. Serum IgG is generally below the lower limit of normal and generally under 400 mg/dL. Most laboratories define the normal reference range as two standard deviations above and below the age-adjusted mean. In addition, IgA and/or IgM should be below the lower limit of normal. One-half of patients have no detectable IgA. IgE is also useful because many patients with CVID have undetectable levels, although IgE levels are not part of the formal diagnostic criteria [<a href="#rid72">72</a>].</p><p>A study of 224 CVID patients reported the following mean immunoglobulin levels at diagnosis [<a href="#rid17">17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>IgG of 258 mg/dL (with a normal reference range of 768 to 1728 mg/dL)</p><p class="bulletIndent1"><span class="glyph">●</span>IgA of 28 mg/dL (with a normal reference range of 99 to 396 mg/dL)</p><p class="bulletIndent1"><span class="glyph">●</span>IgM of 40 mg/dL (with a normal reference range of 38 to 266 mg/dL)</p><p></p><p>Immunoglobulin levels should be repeated to confirm that the values are persistently low and that a laboratory error has not occurred. Repeating levels once is sufficient if patients are in their usual state of health. If there is a concomitant illness that could cause secondarily low immunoglobulin levels (eg, nephrotic syndrome or protein-losing enteropathy), then the measurement should be repeated approximately three months after resolution of the illness. In contrast, neither acute infection, such as pneumonia, nor short-term administration of systemic glucocorticoids should significantly reduce or increase immunoglobulin levels. However, chronic systemic glucocorticoids may reduce serum IgG levels, as reviewed separately. (See  <a class="medical medical_review" href="/d/html/3986.html" rel="external">"Glucocorticoid effects on the immune system"</a>.)</p><p>A few patients with marginally low levels of IgG, borderline or low levels of IgA, and retained antibody function may over time progress to CVID with more complete losses of IgG, IgA, and IgM and loss of functional antibody.</p><p>Patients with CVID may have low, normal, or (rarely) increased levels of IgM. Significantly elevated baseline levels of IgM should prompt consideration of an alternative diagnosis (see  <a class="medical medical_review" href="/d/html/13567.html" rel="external">"Hyperimmunoglobulin M syndromes"</a>)._However, when IgM increases over time, this may suggest worsening lymphoid pulmonary interstitial lung disease (ILD) [<a href="#rid88">88</a>] or, rarely, a developing lymphoid malignancy.</p><p>Serum total IgE levels were undetectable in 76 percent of a large cohort of 354 patients with CVID, and allergen-specific IgE was undetectable in over 96 percent. Less than 1 percent of patients had an elevated total IgE (&gt;180 international units/mL) [<a href="#rid72">72</a>].</p><p>Absence or very low levels of natural antibodies, such as isohemagglutinins, is common. Isohemagglutinins are discussed separately. (See  <a class="medical medical_review" href="/d/html/3903.html" rel="external">"Laboratory evaluation of the immune system"</a> and  <a class="medical medical_review" href="/d/html/3929.html" rel="external">"Assessing antibody function as part of an immunologic evaluation"</a>.)</p><p class="headingAnchor" id="H25760199"><span class="h2">Indications for referral</span><span class="headingEndMark"> — </span>If the patient's history and physical examination raise concern about a possible diagnosis of CVID, immunoglobulin levels should be evaluated initially, as just described. Referral to a clinical immunologist is indicated, whenever possible, to assess vaccine responsiveness and exclude other causes of hypogammaglobulinemia. Immunology specialists can also determine the most appropriate therapies (such as prophylactic antibiotics and <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> replacement) and help monitor the patient for associated disorders.</p><p class="headingAnchor" id="H25760205"><span class="h2">Further immunologic evaluation</span><span class="headingEndMark"> — </span>Once hypogammaglobulinemia has been demonstrated, the patient's ability to respond to vaccines should be assessed.</p><p class="headingAnchor" id="H4"><span class="h2">Vaccine response</span><span class="headingEndMark"> — </span>The patient's response to both protein- and polysaccharide-based vaccines should be assessed in most cases, unless antibody levels are very low (eg, IgG &lt;200 mg/dL) or undetectable, in which case vaccine response can be assumed to be deficient. Acute illness does not generally affect vaccine responsiveness, nor does systemic glucocorticoid therapy, particularly if the daily dose is lower than about 40 mg of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>. (See  <a class="medical medical_review" href="/d/html/3986.html" rel="external">"Glucocorticoid effects on the immune system", section on 'Impact on vaccination'</a>.)</p><p>In adults who received routine vaccinations, the following should be assessed:</p><p class="bulletIndent1"><span class="glyph">●</span>IgG antibodies to tetanus and diphtheria, which provide an estimate of the patient's response to protein-based antigens.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A panel of IgG antibodies to 14 or 23 serotypes of the polysaccharides in the polysaccharide pneumococcal vaccine, which provides an estimate of the patient's response to polysaccharide-based antigens.</p><p></p><p>Patients with CVID usually have impaired responses to both protein and polysaccharide-based vaccines. Evaluation of vaccine response is part of the diagnosis of many immunodeficiencies and is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/3929.html" rel="external">"Assessing antibody function as part of an immunologic evaluation"</a>.)</p><p class="headingAnchor" id="H25760339"><span class="h3">Additional testing</span><span class="headingEndMark"> — </span>Additional testing may include flow cytometry of leukocytes and molecular analysis. However, neither test is required for diagnosis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Flow cytometry</strong> – Although flow cytometry of leukocytes is not required for diagnosis, patients with CVID may show abnormalities. Most patients with CVID have normal numbers of circulating T and B lymphocytes. However, most can be shown to have somewhat reduced levels of circulating memory B cells (CD27+ B cells) and especially low levels of isotype switched memory B cells (CD27+ IgD- IgM-) [<a href="#rid89">89,90</a>]. Increased numbers of transitional B cells are often noted in those with autoimmunity [<a href="#rid91">91</a>]. Some have impaired T cell function. Abnormal cytokine levels have also been described. These findings are not used in diagnosis and are discussed separately. (See  <a class="medical medical_review" href="/d/html/3904.html" rel="external">"Pathogenesis of common variable immunodeficiency"</a> and  <a class="medical medical_review" href="/d/html/3937.html" rel="external">"Flow cytometry for the diagnosis of inborn errors of immunity", section on 'Common variable immunodeficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecular analysis</strong> – Molecular analysis is not required for the diagnosis of CVID, but these studies may be helpful for management. Genome-wide association previously identified diverse associations with CVID [<a href="#rid92">92</a>]. Increasing numbers of genetic defects have been described in subjects with CVID, and 25 to 30 percent of patients will be found to have such gene changes [<a href="#rid93">93-100</a>]. The molecular defects that have been reported in patients with CVID are discussed separately. (See  <a class="medical medical_review" href="/d/html/3904.html" rel="external">"Pathogenesis of common variable immunodeficiency", section on 'Genetics'</a>.)</p><p></p><p class="bulletIndent1">For these reasons, molecular testing might be considered for cases with early onset (before the age of 15 years) or with autoimmune or inflammatory complications or in those with other affected family members, making detection of a discrete defect somewhat more likely [<a href="#rid98">98</a>]. This may aid in therapeutic decisions if a genetic defect is noted that can be addressed with a biologic therapy [<a href="#rid101">101</a>]. Genetic testing is also sometimes useful for excluding other immunodeficiencies that arise from known genetic defects, such as some of the causes of hyperimmunoglobulin M syndromes (HIGM) or agammaglobulinemias. (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>B cell maturation antigen</strong> – Serum B cell maturation antigen (BCMA) is an investigational test in the diagnosis of severe antibody defects. BCMA correlates with the presence of plasma cells in various tissues and was found to be low in patients with CVID and X-linked agammaglobulinemia who had serum IgG levels below 600 mg/dL, indicating that BCMA could be used to identify the more severe disorders of antibody production [<a href="#rid102">102</a>]. Although not commercially available, BCMA could be diagnostically useful in the future, would not be affected by prior administration of <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a>, and could provide information about the patient's potential capacity for antibody production. However, the presence of actual functional antibody would still need to be examined. Prospective studies are needed to confirm the utility of this test in the diagnostic setting.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other biomarkers</strong> – A number of studies have sought useful biomarkers that might help distinguish patients with CVID who develop the numerous noninfectious complications from those with only infections. Examples include potentially useful condition-specific biomarkers, such as [<a href="#rid103">103</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Normal or elevated IgM for lymphoma</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Normal or elevated IgM, increased BAFF (B cell activating factor of the tumor necrosis factor [TNF] family) for progressive ILD [<a href="#rid88">88</a>]</p><p></p><p class="bulletIndent1">Additional biomarkers have provided insights into disease pathogenesis, demonstrating systemic inflammation (increased lipopolysaccharide-binding protein [LBP], sCD14, and sCD25; expanded type 3 innate lymphoid cells [ILC3]), mucosal defects (increased zonulin, intestinal fatty acid-binding protein [I-FABP]), and perhaps reduced antiinflammatory capability with reduced high-density lipoprotein (HDL) levels and other lipid abnormalities noted in CVID [<a href="#rid104">104</a>]. Elevated circulating bioactive bacterial ribosomal deoxyribonucleic acid (rDNA) levels have also been noted in the subset of patients with autoimmune or inflammatory conditions [<a href="#rid103">103,105</a>].</p><p></p><p class="headingAnchor" id="H7"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of CVID can be assigned to a patient over age four years who demonstrates <strong>all</strong> of the following characteristics [<a href="#rid1">1,2,106</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Significantly reduced total serum concentrations of IgG (see <a class="local">'Immunoglobulin levels'</a> above)</p><p class="bulletIndent1"><span class="glyph">●</span>Low IgA and/or IgM</p><p class="bulletIndent1"><span class="glyph">●</span>Poor or absent response to immunization (see <a class="local">'Vaccine response'</a> above)</p><p class="bulletIndent1"><span class="glyph">●</span>The absence of any other defined immunodeficiency state (ie, CVID is a diagnosis of exclusion) (see <a class="local">'Differential diagnosis'</a> below)</p><p></p><p>The diagnosis of IgG deficiency should be differentiated from CVID as the laboratory parameters and clinical outcomes are different [<a href="#rid107">107</a>]. The diagnosis should also not be made definitively in children younger than four years of age, as immune function may not have matured sufficiently. Diagnosis in children is discussed separately. (See  <a class="medical medical_review" href="/d/html/16132.html" rel="external">"Common variable immunodeficiency in children", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of hypogammaglobulinemia, the primary laboratory feature of CVID, is reviewed in this section. There are several other inborn errors of immunity that must be specifically excluded in children and these are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/16132.html" rel="external">"Common variable immunodeficiency in children", section on 'Differential diagnosis'</a>.)</p><p>Hypogammaglobulinemia may be classified as primary or secondary. In adults, secondary causes of hypogammaglobulinemia are far more common than primary causes.</p><p class="headingAnchor" id="H19776367"><span class="h2">Secondary hypogammaglobulinemia</span><span class="headingEndMark"> — </span>A large number of conditions are associated with secondary hypogammaglobulinemia due to either decreased production or increased loss.</p><p class="headingAnchor" id="H19776374"><span class="h3">Decreased production</span><span class="headingEndMark"> — </span>Decreased production of immunoglobulins can be seen with the following disorders:</p><p class="bulletIndent1"><span class="glyph">●</span>Drugs (most commonly immunosuppressants, such as glucocorticoids, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> therapy, and antiseizure medications) (see  <a class="medical medical_review" href="/d/html/3986.html" rel="external">"Glucocorticoid effects on the immune system"</a> and  <a class="medical medical_review" href="/d/html/3939.html" rel="external">"Secondary immunodeficiency induced by biologic therapies"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malignancy and premalignant disorders (such as chronic lymphocytic leukemia, lymphoma, multiple myeloma, or Waldenström macroglobulinemia) [<a href="#rid108">108</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thymoma with hypogammaglobulinemia (Good syndrome) [<a href="#rid109">109,110</a>]</p><p></p><p>It is the author's approach to evaluate for secondary causes of hypogammaglobulinemia if a thorough history, physical examination, and laboratory studies reveal suggestive signs or symptoms, rather than as a matter of course. As an example, we would request an abdominal or chest computed tomography (CT) to exclude lymphoma if a patient reported fever or weight loss.</p><p class="headingAnchor" id="H19776381"><span class="h3">Increased loss</span><span class="headingEndMark"> — </span>Increased loss of immunoglobulins may result from protein-losing enteropathies, such as intestinal lymphangiectasia, nephrotic syndrome, burns, and other traumas leading to loss of fluids. (See  <a class="medical medical_review" href="/d/html/4781.html" rel="external">"Overview of nutrient absorption and etiopathogenesis of malabsorption"</a> and  <a class="medical medical_review" href="/d/html/3084.html" rel="external">"Overview of heavy proteinuria and the nephrotic syndrome", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/3084.html" rel="external">"Overview of heavy proteinuria and the nephrotic syndrome", section on 'Infection'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Primary hypogammaglobulinemia</span><span class="headingEndMark"> — </span>There are several other inborn errors of immunity in which significant reductions of IgG are seen, accompanied by either abnormally high or low IgA or IgM levels. In children, several additional disorders should be excluded, as discussed separately. The discussion here is focused on adults. (See  <a class="medical medical_review" href="/d/html/16132.html" rel="external">"Common variable immunodeficiency in children", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H14472870"><span class="h3">IgG subclass deficiencies</span><span class="headingEndMark"> — </span>Deficiency in IgG1 can cause general hypogammaglobulinemia because IgG1 comprises up to 75 percent of the total serum IgG. IgG2 subclass deficiencies can also lead to mild deficiency of total serum IgG or IgG serum levels at the lower norm and to a poor vaccine response. Subclass deficiencies can also occur in conjunction with IgA deficiency, and some patients demonstrate poor vaccine response. (See  <a class="medical medical_review" href="/d/html/3906.html" rel="external">"IgG subclass deficiency", section on 'IgG1 deficiency'</a>.)</p><p class="headingAnchor" id="H14472930"><span class="h3">Hyperimmunoglobulin M syndromes</span><span class="headingEndMark"> — </span>Hyperimmunoglobulin M syndromes (HIGM) can arise from defects of CD40 ligand, an X-linked disease in which isotype switch from IgM to IgA or IgG does not occur. Other causes of HIGM are rare genetic defects in the nucleic acid-modifying enzymes, called activation-induced cytidine deaminase (AICDA or AID) or uracil nucleoside glycosylase (UNG), or deficiency of CD40 (more rare than defects in CD40 ligand). Class-switching cannot occur without functional AICDA or UNG; therefore, B cells can only produce appreciable quantities of IgM. Patients with AICDA and UNG deficiencies generally present with the recurrent and severe sinopulmonary infections with encapsulated bacteria that are characteristic of antibody deficiencies. Gastrointestinal infections (including <em>Giardiasis</em>), bacterial meningitis, viral encephalitis, and severe hepatitis B infections have also been observed, and patients are susceptible to lymph node hyperplasia and autoimmune disorders.</p><p>Among patients with CD40 ligand, AICDA, and UNG deficiencies, IgG levels are generally &lt;200 mg/dL, while IgA is &lt;20 mg/dL, and IgM ranges from 100 to 3700 mg/dL. IgG specific antibody responses are nonexistent. Numbers of T and B cells in the circulation are normal, and T cell function is intact. (See  <a class="medical medical_review" href="/d/html/13567.html" rel="external">"Hyperimmunoglobulin M syndromes"</a>.)</p><p class="headingAnchor" id="H14473235"><span class="h3">Combined immunodeficiencies</span><span class="headingEndMark"> — </span>Other combined immunodeficiencies that may mimic clinical or laboratory features of CVID and can present after childhood include milder forms of adenosine deaminase deficiency (ADA), hypomorphic recombination-activating gene (<em>RAG</em>) mutations, and Artemis defects.</p><p>It can be difficult to distinguish patients with combined defects from other CVID subjects since there is overlap between the laboratory features of these two groups. With time, this may become easier as the genetic basis of these disorders is defined, but, generally, patients with low CD4 T cells and/or low numbers of CD4 naive T cells are those most likely to have a combined immune defect. These have also been identified as late-onset combined immune defects (LOCID) [<a href="#rid14">14,110</a>]. (See  <a class="medical medical_review" href="/d/html/3935.html" rel="external">"Combined immunodeficiencies: An overview"</a>.)</p><p class="headingAnchor" id="H3657621794"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112831.html" rel="external">"Society guideline links: Inborn errors of immunity (previously called primary immunodeficiencies)"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fprimaryimmune.org%2F&amp;token=bL4RqHo8CPPVJDTM0%2BcTmkTM12oVIegmgK8pcWp0TAEePaxWkuUPqswe7oao%2F9D5&amp;TOPIC_ID=3928" target="_blank">Immune Deficiency Foundation</a> and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Finfo4pi.org%2F&amp;token=59lhmQPXII8chGUZ6%2BhIdBrYwvCfMa6844Cju3wUA00%3D&amp;TOPIC_ID=3928" target="_blank">Jeffrey Modell Foundation</a> have links and information for patients about CVID.</p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Common variable immunodeficiency (CVID) is the most common form of severe antibody deficiency affecting both children and adults. The characteristic immune defect in CVID is impaired B cell differentiation with defective production of immunoglobulin. CVID is defined by low total serum concentrations of immunoglobulin G (IgG), as well as low immunoglobulin A (IgA) and/or immunoglobulin M (IgM), poor or absent response to immunization, and the absence of any other defined immunodeficiency state. (See <a class="local">'Introduction'</a> above and <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Age of onset is variable. Most patients are diagnosed between the ages of 20 and 40 years. Delayed recognition is common. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Typical infections</strong> – Bacterial infections of the sinopulmonary tract, particularly sinusitis and pneumonia, are experienced by most patients with CVID  (<a class="graphic graphic_table graphicRef89794" href="/d/graphic/89794.html" rel="external">table 1</a>). Opportunistic and unusual infections are uncommon but do occur. (See <a class="local">'Infections'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Noninfectious manifestations</strong> – In addition to recurrent infections, patients with CVID have evidence of immune dysregulation leading to autoimmunity, a variety of inflammatory disorders, and malignant disease. Patients may suffer from chronic lung disease, gastrointestinal and liver disorders, granulomatous infiltrations, lymphoid hyperplasia, splenomegaly, or malignancy. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic lung diseases, especially interstitial lung disease (ILD) and/or bronchiectasis, are seen in 30 to 50 percent of patients and represent an important cause of morbidity and mortality. (See <a class="local">'Pulmonary disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gastrointestinal disease is present in approximately 20 percent of CVID patients, with a variety of different disorders described. The pathophysiology of most of these disorders is not known. Chronic diarrhea is the most common presenting gastrointestinal symptom. Chronic infections with <em>Giardia</em>, cytomegalovirus, and <em>Cryptosporidium</em> are also reported  (<a class="graphic graphic_table graphicRef89794" href="/d/graphic/89794.html" rel="external">table 1</a>). (See <a class="local">'Gastrointestinal disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Autoimmune conditions develop in 20 to 35 percent of patients with CVID, particularly hemolytic anemia, thrombocytopenia, and rheumatoid arthritis, and an estimated 8 to 20 percent of patients have some form of granulomatous disease. (See <a class="local">'Granulomatous lung disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with CVID are at increased risk for malignancies and have a particular susceptibility to non-Hodgkin lymphomas (NHLs). (See <a class="local">'Malignancies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and diagnosis</strong> – The diagnosis of CVID requires a suggestive clinical history, a reduced total serum concentration of IgG plus low IgA or IgM, and poor responses to both protein- and polysaccharide-based vaccines. (See <a class="local">'Evaluation'</a> above and <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – Various forms of primary and secondary hypogammaglobulinemia must be excluded before the diagnosis of CVID can be assigned. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bonilla FA, Barlan I, Chapel H, et al. International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. J Allergy Clin Immunol Pract 2016; 4:38.</a></li><li><a class="nounderline abstract_t">Seidel MG, Kindle G, Gathmann B, et al. The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity. J Allergy Clin Immunol Pract 2019; 7:1763.</a></li><li><a class="nounderline abstract_t">Hammarström L, Vorechovsky I, Webster D. Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID). Clin Exp Immunol 2000; 120:225.</a></li><li><a class="nounderline abstract_t">Hermaszewski RA, Webster AD. Primary hypogammaglobulinaemia: a survey of clinical manifestations and complications. Q J Med 1993; 86:31.</a></li><li><a class="nounderline abstract_t">Gathmann B, Mahlaoui N, CEREDIH, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol 2014; 134:116.</a></li><li><a class="nounderline abstract_t">Oksenhendler E, Gérard L, Fieschi C, et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis 2008; 46:1547.</a></li><li><a class="nounderline abstract_t">Gathmann B, Goldacker S, Klima M, et al. The German national registry for primary immunodeficiencies (PID). Clin Exp Immunol 2013; 173:372.</a></li><li><a class="nounderline abstract_t">Sullivan KE, Puck JM, Notarangelo LD, et al. USIDNET: a strategy to build a community of clinical immunologists. J Clin Immunol 2014; 34:428.</a></li><li><a class="nounderline abstract_t">Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999; 92:34.</a></li><li><a class="nounderline abstract_t">Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood 2012; 119:1650.</a></li><li><a class="nounderline abstract_t">Kainulainen L, Nikoskelainen J, Ruuskanen O. Diagnostic findings in 95 Finnish patients with common variable immunodeficiency. J Clin Immunol 2001; 21:145.</a></li><li><a class="nounderline abstract_t">Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 2008; 112:277.</a></li><li><a class="nounderline abstract_t">Cunningham-Rundles C. Common variable immune deficiency: Dissection of the variable. Immunol Rev 2019; 287:145.</a></li><li><a class="nounderline abstract_t">Malphettes M, Gérard L, Carmagnat M, et al. Late-onset combined immune deficiency: a subset of common variable immunodeficiency with severe T cell defect. Clin Infect Dis 2009; 49:1329.</a></li><li><a class="nounderline abstract_t">Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010; 125:1354.</a></li><li><a class="nounderline abstract_t">Roifman CM, Rao CP, Lederman HM, et al. Increased susceptibility to Mycoplasma infection in patients with hypogammaglobulinemia. Am J Med 1986; 80:590.</a></li><li><a class="nounderline abstract_t">Quinti I, Soresina A, Spadaro G, et al. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol 2007; 27:308.</a></li><li><a class="nounderline abstract_t">Micol R, Kayal S, Mahlaoui N, et al. Protective effect of IgM against colonization of the respiratory tract by nontypeable Haemophilus influenzae in patients with hypogammaglobulinemia. J Allergy Clin Immunol 2012; 129:770.</a></li><li><a class="nounderline abstract_t">Pulvirenti F, Camilli R, Giufrè M, et al. Risk factors for Haemophilus influenzae and pneumococcal respiratory tract colonization in CVID. J Allergy Clin Immunol 2018; 142:1999.</a></li><li><a class="nounderline abstract_t">Busse PJ, Farzan S, Cunningham-Rundles C. Pulmonary complications of common variable immunodeficiency. Ann Allergy Asthma Immunol 2007; 98:1.</a></li><li><a class="nounderline abstract_t">Bang TJ, Richards JC, Olson AL, et al. Pulmonary Manifestations of Common Variable Immunodeficiency. J Thorac Imaging 2018; 33:377.</a></li><li><a class="nounderline abstract_t">Kainulainen L, Suonpää J, Nikoskelainen J, et al. Bacteria and viruses in maxillary sinuses of patients with primary hypogammaglobulinemia. Arch Otolaryngol Head Neck Surg 2007; 133:597.</a></li><li><a class="nounderline abstract_t">Agarwal S, Mayer L. Pathogenesis and treatment of gastrointestinal disease in antibody deficiency syndromes. J Allergy Clin Immunol 2009; 124:658.</a></li><li><a class="nounderline abstract_t">Uzzan M, Ko HM, Mehandru S, Cunningham-Rundles C. Gastrointestinal Disorders Associated with Common Variable Immune Deficiency (CVID) and Chronic Granulomatous Disease (CGD). Curr Gastroenterol Rep 2016; 18:17.</a></li><li><a class="nounderline abstract_t">Woodward JM, Gkrania-Klotsas E, Cordero-Ng AY, et al. The role of chronic norovirus infection in the enteropathy associated with common variable immunodeficiency. Am J Gastroenterol 2015; 110:320.</a></li><li><a class="nounderline abstract_t">Brown LK, Ruis C, Clark I, et al. A comprehensive characterization of chronic norovirus infection in immunodeficient hosts. J Allergy Clin Immunol 2019; 144:1450.</a></li><li><a class="nounderline abstract_t">Franz A, Webster AD, Furr PM, Taylor-Robinson D. Mycoplasmal arthritis in patients with primary immunoglobulin deficiency: clinical features and outcome in 18 patients. Br J Rheumatol 1997; 36:661.</a></li><li><a class="nounderline abstract_t">Azizi G, Kiaee F, Hedayat E, et al. Rheumatologic complications in a cohort of 227 patients with common variable immunodeficiency. Scand J Immunol 2018; 87:e12663.</a></li><li><a class="nounderline abstract_t">Hill LE. Hypogammaglobulinaemia in the United Kingdom. 3. Clinical features of hypogammaglobulinaemia. Spec Rep Ser Med Res Counc (G B) 1971; 310:9.</a></li><li><a class="nounderline abstract_t">Urschel S, Kayikci L, Wintergerst U, et al. Common variable immunodeficiency disorders in children: delayed diagnosis despite typical clinical presentation. J Pediatr 2009; 154:888.</a></li><li><a class="nounderline abstract_t">Kainulainen L, Varpula M, Liippo K, et al. Pulmonary abnormalities in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol 1999; 104:1031.</a></li><li><a class="nounderline abstract_t">Orange JS, Ballow M, Stiehm ER, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma &amp; Immunology. J Allergy Clin Immunol 2012; 130:S1.</a></li><li><a class="nounderline abstract_t">Maglione PJ, Overbey JR, Cunningham-Rundles C. Progression of Common Variable Immunodeficiency Interstitial Lung Disease Accompanies Distinct Pulmonary and Laboratory Findings. J Allergy Clin Immunol Pract 2015; 3:941.</a></li><li><a class="nounderline abstract_t">Maglione PJ, Overbey JR, Radigan L, et al. Pulmonary radiologic findings in common variable immunodeficiency: clinical and immunological correlations. Ann Allergy Asthma Immunol 2014; 113:452.</a></li><li><a class="nounderline abstract_t">Verma N, Grimbacher B, Hurst JR. Lung disease in primary antibody deficiency. Lancet Respir Med 2015; 3:651.</a></li><li><a class="nounderline abstract_t">Kellner ES, Fuleihan R, Cunningham-Rundles C, et al. Cellular Defects in CVID Patients with Chronic Lung Disease in the USIDNET Registry. J Clin Immunol 2019; 39:569.</a></li><li><a class="nounderline abstract_t">Weinberger T, Fuleihan R, Cunningham-Rundles C, Maglione PJ. Factors Beyond Lack of Antibody Govern Pulmonary Complications in Primary Antibody Deficiency. J Clin Immunol 2019; 39:440.</a></li><li><a class="nounderline abstract_t">Schütz K, Alecsandru D, Grimbacher B, et al. Correction to: Imaging of Bronchial Pathology in Antibody Deficiency: Data from the European Chest CT Group. J Clin Immunol 2019; 39:225.</a></li><li><a class="nounderline abstract_t">Agondi RC, Barros MT, Rizzo LV, et al. Allergic asthma in patients with common variable immunodeficiency. Allergy 2010; 65:510.</a></li><li><a class="nounderline abstract_t">Mechanic LJ, Dikman S, Cunningham-Rundles C. Granulomatous disease in common variable immunodeficiency. Ann Intern Med 1997; 127:613.</a></li><li><a class="nounderline abstract_t">Park JE, Beal I, Dilworth JP, et al. The HRCT appearances of granulomatous pulmonary disease in common variable immune deficiency. Eur J Radiol 2005; 54:359.</a></li><li><a class="nounderline abstract_t">Maglione PJ, Ko HM, Beasley MB, et al. Tertiary lymphoid neogenesis is a component of pulmonary lymphoid hyperplasia in patients with common variable immunodeficiency. J Allergy Clin Immunol 2014; 133:535.</a></li><li><a class="nounderline abstract_t">Bintalib HM, van de Ven A, Jacob J, et al. Diagnostic testing for interstitial lung disease in common variable immunodeficiency: a systematic review. Front Immunol 2023; 14:1190235.</a></li><li><a class="nounderline abstract_t">Bates CA, Ellison MC, Lynch DA, et al. Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency. J Allergy Clin Immunol 2004; 114:415.</a></li><li><a class="nounderline abstract_t">Park JH, Levinson AI. Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID). Clin Immunol 2010; 134:97.</a></li><li><a class="nounderline abstract_t">Hurst JR, Verma N, Lowe D, et al. British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders. J Allergy Clin Immunol Pract 2017; 5:938.</a></li><li><a class="nounderline abstract_t">Mannina A, Chung JH, Swigris JJ, et al. Clinical Predictors of a Diagnosis of Common Variable Immunodeficiency-related Granulomatous-Lymphocytic Interstitial Lung Disease. Ann Am Thorac Soc 2016; 13:1042.</a></li><li><a class="nounderline abstract_t">Cinetto F, Scarpa R, Carrabba M, et al. Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) in Common Variable Immunodeficiency (CVID): A Multicenter Retrospective Study of Patients From Italian PID Referral Centers. Front Immunol 2021; 12:627423.</a></li><li><a class="nounderline abstract_t">Ardeniz O, Cunningham-Rundles C. Granulomatous disease in common variable immunodeficiency. Clin Immunol 2009; 133:198.</a></li><li><a class="nounderline abstract_t">Artac H, Bozkurt B, Talim B, Reisli I. Sarcoid-like granulomas in common variable immunodeficiency. Rheumatol Int 2009; 30:109.</a></li><li><a class="nounderline abstract_t">Boursiquot JN, Gérard L, Malphettes M, et al. Granulomatous disease in CVID: retrospective analysis of clinical characteristics and treatment efficacy in a cohort of 59 patients. J Clin Immunol 2013; 33:84.</a></li><li><a class="nounderline abstract_t">Fasano MB, Sullivan KE, Sarpong SB, et al. Sarcoidosis and common variable immunodeficiency. Report of 8 cases and review of the literature. Medicine (Baltimore) 1996; 75:251.</a></li><li><a class="nounderline abstract_t">Arnold DF, Wiggins J, Cunningham-Rundles C, et al. Granulomatous disease: distinguishing primary antibody disease from sarcoidosis. Clin Immunol 2008; 128:18.</a></li><li><a class="nounderline abstract_t">Mullighan CG, Fanning GC, Chapel HM, Welsh KI. TNF and lymphotoxin-alpha polymorphisms associated with common variable immunodeficiency: role in the pathogenesis of granulomatous disease. J Immunol 1997; 159:6236.</a></li><li><a class="nounderline abstract_t">Marashi SM, Raeiszadeh M, Workman S, et al. Inflammation in common variable immunodeficiency is associated with a distinct CD8(+) response to cytomegalovirus. J Allergy Clin Immunol 2011; 127:1385.</a></li><li><a class="nounderline abstract_t">Washington K, Stenzel TT, Buckley RH, Gottfried MR. Gastrointestinal pathology in patients with common variable immunodeficiency and X-linked agammaglobulinemia. Am J Surg Pathol 1996; 20:1240.</a></li><li><a class="nounderline abstract_t">Pikkarainen S, Martelius T, Ristimäki A, et al. A High Prevalence of Gastrointestinal Manifestations in Common Variable Immunodeficiency. Am J Gastroenterol 2019; 114:648.</a></li><li><a class="nounderline abstract_t">Strohmeier V, Andrieux G, Unger S, et al. Interferon-Driven Immune Dysregulation in Common Variable Immunodeficiency-Associated Villous Atrophy and Norovirus Infection. J Clin Immunol 2023; 43:371.</a></li><li><a class="nounderline abstract_t">Bayraktar Y, Ersoy O, Sokmensuer C. The findings of capsule endoscopy in patients with common variable immunodeficiency syndrome. Hepatogastroenterology 2007; 54:1034.</a></li><li><a class="nounderline abstract_t">Maarschalk-Ellerbroek LJ, Oldenburg B, Mombers IM, et al. Outcome of screening endoscopy in common variable immunodeficiency disorder and X-linked agammaglobulinemia. Endoscopy 2013; 45:320.</a></li><li><a class="nounderline abstract_t">Lai Ping So A, Mayer L. Gastrointestinal manifestations of primary immunodeficiency disorders. Semin Gastrointest Dis 1997; 8:22.</a></li><li><a class="nounderline abstract_t">Daniels JA, Lederman HM, Maitra A, Montgomery EA. Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID): a clinicopathologic study and review. Am J Surg Pathol 2007; 31:1800.</a></li><li><a class="nounderline abstract_t">Detková D, de Gracia J, Lopes-da-Silva S, et al. Common variable immunodeficiency: association between memory B cells and lung diseases. Chest 2007; 131:1883.</a></li><li><a class="nounderline abstract_t">Boileau J, Mouillot G, Gérard L, et al. Autoimmunity in common variable immunodeficiency: correlation with lymphocyte phenotype in the French DEFI study. J Autoimmun 2011; 36:25.</a></li><li><a class="nounderline abstract_t">Agarwal S, Cunningham-Rundles C. Autoimmunity in common variable immunodeficiency. Ann Allergy Asthma Immunol 2019; 123:454.</a></li><li><a class="nounderline abstract_t">Mormile I, Punziano A, Riolo CA, et al. Common Variable Immunodeficiency and Autoimmune Diseases: A Retrospective Study of 95 Adult Patients in a Single Tertiary Care Center. Front Immunol 2021; 12:652487.</a></li><li><a class="nounderline abstract_t">Wang J, Cunningham-Rundles C. Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). J Autoimmun 2005; 25:57.</a></li><li><a class="nounderline abstract_t">Sève P, Bourdillon L, Sarrot-Reynauld F, et al. Autoimmune hemolytic anemia and common variable immunodeficiency: a case-control study of 18 patients. Medicine (Baltimore) 2008; 87:177.</a></li><li><a class="nounderline abstract_t">Giannouli S, Anagnostou D, Soliotis F, Voulgarelis M. Autoimmune manifestations in common variable immunodeficiency. Clin Rheumatol 2004; 23:449.</a></li><li><a class="nounderline abstract_t">Arunachalam M, Sanzo M, Lotti T, et al. Common variable immunodeficiency in vitiligo. G Ital Dermatol Venereol 2010; 145:783.</a></li><li><a class="nounderline abstract_t">Fernández-Castro M, Mellor-Pita S, Citores MJ, et al. Common variable immunodeficiency in systemic lupus erythematosus. Semin Arthritis Rheum 2007; 36:238.</a></li><li><a class="nounderline abstract_t">Lawrence MG, Palacios-Kibler TV, Workman LJ, et al. Low Serum IgE Is a Sensitive and Specific Marker for Common Variable Immunodeficiency (CVID). J Clin Immunol 2018; 38:225.</a></li><li><a class="nounderline abstract_t">Ward C, Lucas M, Piris J, et al. Abnormal liver function in common variable immunodeficiency disorders due to nodular regenerative hyperplasia. Clin Exp Immunol 2008; 153:331.</a></li><li><a class="nounderline abstract_t">Malamut G, Verkarre V, Suarez F, et al. The enteropathy associated with common variable immunodeficiency: the delineated frontiers with celiac disease. Am J Gastroenterol 2010; 105:2262.</a></li><li><a class="nounderline abstract_t">Fuss IJ, Friend J, Yang Z, et al. Nodular regenerative hyperplasia in common variable immunodeficiency. J Clin Immunol 2013; 33:748.</a></li><li><a class="nounderline abstract_t">Mayor PC, Eng KH, Singel KL, et al. Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol 2018; 141:1028.</a></li><li><a class="nounderline abstract_t">Cunningham-Rundles C. Hematologic complications of primary immune deficiencies. Blood Rev 2002; 16:61.</a></li><li><a class="nounderline abstract_t">Mellemkjaer L, Hammarstrom L, Andersen V, et al. Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study. Clin Exp Immunol 2002; 130:495.</a></li><li><a class="nounderline abstract_t">Vajdic CM, Mao L, van Leeuwen MT, et al. Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency? Blood 2010; 116:1228.</a></li><li><a class="nounderline abstract_t">Cunningham-Rundles C, Siegal FP, Cunningham-Rundles S, Lieberman P. Incidence of cancer in 98 patients with common varied immunodeficiency. J Clin Immunol 1987; 7:294.</a></li><li><a class="nounderline abstract_t">Smith T, Cunningham-Rundles C. Lymphoid malignancy in common variable immunodeficiency in a single-center cohort. Eur J Haematol 2021; 107:503.</a></li><li><a class="nounderline abstract_t">Aghamohammadi A, Rezaei N, Gharagozlou M, et al. Hodgkin lymphoma in two siblings with common variable immunodeficiency. Pediatr Hematol Oncol 2007; 24:337.</a></li><li><a class="nounderline abstract_t">Kinlen LJ, Webster AD, Bird AG, et al. Prospective study of cancer in patients with hypogammaglobulinaemia. Lancet 1985; 1:263.</a></li><li><a class="nounderline abstract_t">Dhalla F, da Silva SP, Lucas M, et al. Review of gastric cancer risk factors in patients with common variable immunodeficiency disorders, resulting in a proposal for a surveillance programme. Clin Exp Immunol 2011; 165:1.</a></li><li><a class="nounderline abstract_t">Zullo A, Romiti A, Rinaldi V, et al. Gastric pathology in patients with common variable immunodeficiency. Gut 1999; 45:77.</a></li><li><a class="nounderline abstract_t">Cunningham-Rundles C. How I treat common variable immune deficiency. Blood 2010; 116:7.</a></li><li><a class="nounderline abstract_t">Sanchez LA, Maggadottir SM, Pantell MS, et al. Two Sides of the Same Coin: Pediatric-Onset and Adult-Onset Common Variable Immune Deficiency. J Clin Immunol 2017; 37:592.</a></li><li><a class="nounderline abstract_t">Maglione PJ, Gyimesi G, Cols M, et al. BAFF-driven B cell hyperplasia underlies lung disease in common variable immunodeficiency. JCI Insight 2019; 4.</a></li><li><a class="nounderline abstract_t">Wehr C, Kivioja T, Schmitt C, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood 2008; 111:77.</a></li><li><a class="nounderline abstract_t">Sánchez-Ramón S, Radigan L, Yu JE, et al. Memory B cells in common variable immunodeficiency: clinical associations and sex differences. Clin Immunol 2008; 128:314.</a></li><li><a class="nounderline abstract_t">Friman V, Quinti I, Davydov AN, et al. Defective peripheral B cell selection in common variable immune deficiency patients with autoimmune manifestations. Cell Rep 2023; 42:112446.</a></li><li><a class="nounderline abstract_t">Orange JS, Glessner JT, Resnick E, et al. Genome-wide association identifies diverse causes of common variable immunodeficiency. J Allergy Clin Immunol 2011; 127:1360.</a></li><li><a class="nounderline abstract_t">Bogaert DJ, Dullaers M, Lambrecht BN, et al. Genes associated with common variable immunodeficiency: one diagnosis to rule them all? J Med Genet 2016; 53:575.</a></li><li><a class="nounderline abstract_t">Maffucci P, Filion CA, Boisson B, et al. Genetic Diagnosis Using Whole Exome Sequencing in Common Variable Immunodeficiency. Front Immunol 2016; 7:220.</a></li><li><a class="nounderline abstract_t">de Valles-Ibáñez G, Esteve-Solé A, Piquer M, et al. Evaluating the Genetics of Common Variable Immunodeficiency: Monogenetic Model and Beyond. Front Immunol 2018; 9:636.</a></li><li><a class="nounderline abstract_t">Tuijnenburg P, Lango Allen H, Burns SO, et al. Loss-of-function nuclear factor κB subunit 1 (NFKB1) variants are the most common monogenic cause of common variable immunodeficiency in Europeans. J Allergy Clin Immunol 2018; 142:1285.</a></li><li><a class="nounderline abstract_t">Rojas-Restrepo J, Caballero-Oteyza A, Huebscher K, et al. Establishing the Molecular Diagnoses in a Cohort of 291 Patients With Predominantly Antibody Deficiency by Targeted Next-Generation Sequencing: Experience From a Monocentric Study. Front Immunol 2021; 12:786516.</a></li><li><a class="nounderline abstract_t">Abolhassani H, Hammarström L, Cunningham-Rundles C. Current genetic landscape in common variable immune deficiency. Blood 2020; 135:656.</a></li><li><a class="nounderline abstract_t">Ramirez NJ, Posadas-Cantera S, Caballero-Oteyza A, et al. There is no gene for CVID - novel monogenetic causes for primary antibody deficiency. Curr Opin Immunol 2021; 72:176.</a></li><li><a class="nounderline abstract_t">Peng XP, Caballero-Oteyza A, Grimbacher B. Common Variable Immunodeficiency: More Pathways than Roads to Rome. Annu Rev Pathol 2023; 18:283.</a></li><li><a class="nounderline abstract_t">Fevang B. Treatment of inflammatory complications in common variable immunodeficiency (CVID): current concepts and future perspectives. Expert Rev Clin Immunol 2023; 19:627.</a></li><li><a class="nounderline abstract_t">Maglione PJ, Ko HM, Tokuyama M, et al. Serum B-Cell Maturation Antigen (BCMA) Levels Differentiate Primary Antibody Deficiencies. J Allergy Clin Immunol Pract 2020; 8:283.</a></li><li><a class="nounderline abstract_t">Ho HE, Cunningham-Rundles C. Seeking Relevant Biomarkers in Common Variable Immunodeficiency. Front Immunol 2022; 13:857050.</a></li><li><a class="nounderline abstract_t">Jorgensen SF, Macpherson ME, Skarpengland T, et al. Disturbed lipid profile in common variable immunodeficiency - a pathogenic loop of inflammation and metabolic disturbances. Front Immunol 2023; 14:1199727.</a></li><li><a class="nounderline abstract_t">Ho HE, Radigan L, Bongers G, et al. Circulating bioactive bacterial DNA is associated with immune activation and complications in common variable immunodeficiency. JCI Insight 2021; 6.</a></li><li><a class="nounderline abstract_t">von Spee-Mayer C, Koemm V, Wehr C, et al. Evaluating laboratory criteria for combined immunodeficiency in adult patients diagnosed with common variable immunodeficiency. Clin Immunol 2019; 203:59.</a></li><li><a class="nounderline abstract_t">Filion CA, Taylor-Black S, Maglione PJ, et al. Differentiation of Common Variable Immunodeficiency From IgG Deficiency. J Allergy Clin Immunol Pract 2019; 7:1277.</a></li><li><a class="nounderline abstract_t">Hunter ZR, Manning RJ, Hanzis C, et al. IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia. Haematologica 2010; 95:470.</a></li><li><a class="nounderline abstract_t">Kelesidis T, Yang O. Good's syndrome remains a mystery after 55 years: A systematic review of the scientific evidence. Clin Immunol 2010; 135:347.</a></li><li><a class="nounderline abstract_t">Kabir A, Alizadehfar R, Tsoukas CM. Good's Syndrome: Time to Move on From Reviewing the Past. Front Immunol 2021; 12:815710.</a></li></ol></div><div id="topicVersionRevision">Topic 3928 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26563668" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : International Consensus Document (ICON): Common Variable Immunodeficiency Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30776527" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10792368" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8438047" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Primary hypogammaglobulinaemia: a survey of clinical manifestations and complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24582312" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical picture and treatment of 2212 patients with common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419489" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Infections in 252 patients with common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23607573" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The German national registry for primary immunodeficiencies (PID).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24711005" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : USIDNET: a strategy to build a community of clinical immunologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10413651" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Common variable immunodeficiency: clinical and immunological features of 248 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22180439" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Morbidity and mortality in common variable immune deficiency over 4 decades.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11332653" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Diagnostic findings in 95 Finnish patients with common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18319398" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Common variable immunodeficiency disorders: division into distinct clinical phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30565247" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Common variable immune deficiency: Dissection of the variable.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19807277" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Late-onset combined immune deficiency: a subset of common variable immunodeficiency with severe T cell defect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20471071" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3963038" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Increased susceptibility to Mycoplasma infection in patients with hypogammaglobulinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17510807" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22153772" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Protective effect of IgM against colonization of the respiratory tract by nontypeable Haemophilus influenzae in patients with hypogammaglobulinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30170126" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Risk factors for Haemophilus influenzae and pneumococcal respiratory tract colonization in CVID.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17225714" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pulmonary complications of common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30067570" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pulmonary Manifestations of Common Variable Immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17576911" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Bacteria and viruses in maxillary sinuses of patients with primary hypogammaglobulinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19665769" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pathogenesis and treatment of gastrointestinal disease in antibody deficiency syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26951230" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Gastrointestinal Disorders Associated with Common Variable Immune Deficiency (CVID) and Chronic Granulomatous Disease (CGD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25623655" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The role of chronic norovirus infection in the enteropathy associated with common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31415785" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A comprehensive characterization of chronic norovirus infection in immunodeficient hosts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9236676" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Mycoplasmal arthritis in patients with primary immunoglobulin deficiency: clinical features and outcome in 18 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29574865" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Rheumatologic complications in a cohort of 227 patients with common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5573491" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Hypogammaglobulinaemia in the United Kingdom. 3. Clinical features of hypogammaglobulinaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19230900" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Common variable immunodeficiency disorders in children: delayed diagnosis despite typical clinical presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10550749" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pulmonary abnormalities in patients with primary hypogammaglobulinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22935624" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma&amp;Immunology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26372540" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Progression of Common Variable Immunodeficiency Interstitial Lung Disease Accompanies Distinct Pulmonary and Laboratory Findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24880814" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pulmonary radiologic findings in common variable immunodeficiency: clinical and immunological correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26188881" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Lung disease in primary antibody deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31250334" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cellular Defects in CVID Patients with Chronic Lung Disease in the USIDNET Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31089938" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Factors Beyond Lack of Antibody Govern Pulmonary Complications in Primary Antibody Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30905051" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Correction to: Imaging of Bronchial Pathology in Antibody Deficiency: Data from the European Chest CT Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19839975" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Allergic asthma in patients with common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9341059" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Granulomatous disease in common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15899336" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The HRCT appearances of granulomatous pulmonary disease in common variable immune deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24131823" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Tertiary lymphoid neogenesis is a component of pulmonary lymphoid hyperplasia in patients with common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37223103" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Diagnostic testing for interstitial lung disease in common variable immunodeficiency: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15316526" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19900842" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28351785" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27064856" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinical Predictors of a Diagnosis of Common Variable Immunodeficiency-related Granulomatous-Lymphocytic Interstitial Lung Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33777011" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) in Common Variable Immunodeficiency (CVID): A Multicenter Retrospective Study of Patients From Italian PID Referral Centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19716342" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Granulomatous disease in common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19326121" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Sarcoid-like granulomas in common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22986767" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Granulomatous disease in CVID: retrospective analysis of clinical characteristics and treatment efficacy in a cohort of 59 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8862347" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Sarcoidosis and common variable immunodeficiency. Report of 8 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18486555" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Granulomatous disease: distinguishing primary antibody disease from sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9550427" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : TNF and lymphotoxin-alpha polymorphisms associated with common variable immunodeficiency: role in the pathogenesis of granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21536322" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Inflammation in common variable immunodeficiency is associated with a distinct CD8(+) response to cytomegalovirus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8827031" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Gastrointestinal pathology in patients with common variable immunodeficiency and X-linked agammaglobulinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30747770" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A High Prevalence of Gastrointestinal Manifestations in Common Variable Immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36282455" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Interferon-Driven Immune Dysregulation in Common Variable Immunodeficiency-Associated Villous Atrophy and Norovirus Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17629033" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The findings of capsule endoscopy in patients with common variable immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23325698" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Outcome of screening endoscopy in common variable immunodeficiency disorder and X-linked agammaglobulinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9000499" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Gastrointestinal manifestations of primary immunodeficiency disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18043034" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID): a clinicopathologic study and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17400689" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Common variable immunodeficiency: association between memory B cells and lung diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21075598" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Autoimmunity in common variable immunodeficiency: correlation with lymphocyte phenotype in the French DEFI study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31349011" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Autoimmunity in common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34290696" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Common Variable Immunodeficiency and Autoimmune Diseases: A Retrospective Study of 95 Adult Patients in a Single Tertiary Care Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15994061" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18520327" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Autoimmune hemolytic anemia and common variable immunodeficiency: a case-control study of 18 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15278751" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Autoimmune manifestations in common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21139556" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Common variable immunodeficiency in vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17276173" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Common variable immunodeficiency in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29453744" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Low Serum IgE Is a Sensitive and Specific Marker for Common Variable Immunodeficiency (CVID).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18647320" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Abnormal liver function in common variable immunodeficiency disorders due to nodular regenerative hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20551941" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The enteropathy associated with common variable immunodeficiency: the delineated frontiers with celiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23420139" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Nodular regenerative hyperplasia in common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28606585" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11913998" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Hematologic complications of primary immune deficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12452841" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20466855" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3611296" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Incidence of cancer in 98 patients with common varied immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34255892" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Lymphoid malignancy in common variable immunodeficiency in a single-center cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17613878" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Hodgkin lymphoma in two siblings with common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2857327" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Prospective study of cancer in patients with hypogammaglobulinaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21470209" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Review of gastric cancer risk factors in patients with common variable immunodeficiency disorders, resulting in a proposal for a surveillance programme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10369708" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Gastric pathology in patients with common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20332369" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : How I treat common variable immune deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28755066" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Two Sides of the Same Coin: Pediatric-Onset and Adult-Onset Common Variable Immune Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30843876" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : BAFF-driven B cell hyperplasia underlies lung disease in common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17898316" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : The EUROclass trial: defining subgroups in common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18620909" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Memory B cells in common variable immunodeficiency: clinical associations and sex differences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37119135" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Defective peripheral B cell selection in common variable immune deficiency patients with autoimmune manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21497890" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Genome-wide association identifies diverse causes of common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27250108" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Genes associated with common variable immunodeficiency: one diagnosis to rule them all?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27379089" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Genetic Diagnosis Using Whole Exome Sequencing in Common Variable Immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29867916" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Evaluating the Genetics of Common Variable Immunodeficiency: Monogenetic Model and Beyond.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29477724" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Loss-of-function nuclear factorκB subunit 1 (NFKB1) variants are the most common monogenic cause of common variable immunodeficiency in Europeans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34975878" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Establishing the Molecular Diagnoses in a Cohort of 291 Patients With Predominantly Antibody Deficiency by Targeted Next-Generation Sequencing: Experience From a Monocentric Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31942606" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Current genetic landscape in common variable immune deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34153571" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : There is no gene for CVID - novel monogenetic causes for primary antibody deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36266261" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Common Variable Immunodeficiency: More Pathways than Roads to Rome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36996348" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Treatment of inflammatory complications in common variable immunodeficiency (CVID): current concepts and future perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31430592" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Serum B-Cell Maturation Antigen (BCMA) Levels Differentiate Primary Antibody Deficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35359997" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Seeking Relevant Biomarkers in Common Variable Immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37545531" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Disturbed lipid profile in common variable immunodeficiency - a pathogenic loop of inflammation and metabolic disturbances.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34622805" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Circulating bioactive bacterial DNA is associated with immune activation and complications in common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31004792" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Evaluating laboratory criteria for combined immunodeficiency in adult patients diagnosed with common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30557717" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Differentiation of Common Variable Immunodeficiency From IgG Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19903677" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20149753" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Good's syndrome remains a mystery after 55 years: A systematic review of the scientific evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35095915" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Good's Syndrome: Time to Move on From Reviewing the Past.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
